Year: 2019
Type: editorial
Abstract: Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid malignancies, but responses are heterogeneous with benefit generally limited to only a fraction of patients.
Source: Annals of Translational Medicine
Institution: Cedars-Sinai Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2981729021